Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143389 · ClinicalTrials.gov registry record · Phase 2
Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
A Phase 2 study, sponsored by Price Vision Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 510
- Enrollment target
NCT01143389 is a Phase 2 study that has completed, run by Price Vision Group. The registered enrollment target is 510 participants.
The verdict
NCT01143389, a Phase 2 study, has completed, sponsored by Price Vision Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 510 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.
Interventions
- DRUG Riboflavin
- DEVICE UVX light
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2010-05 |
| Est. Completion | 2017-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01143389
The ClinicalTrials.gov registry entry for NCT01143389 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Price Vision Group, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Riboflavin is the first listed.
NCT01143389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01143389 about?
NCT01143389 is a clinical study titled "Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia". The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.
What is the current status of trial NCT01143389?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 510 participants. The study started on 2010-05. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT01143389?
The interventions under investigation include: Riboflavin (DRUG), UVX light (DEVICE).
Who is sponsoring clinical trial NCT01143389?
This trial is sponsored by Price Vision Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.